Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer Journal Article uri icon
  • BACKGROUND: Pain is associated with shorter survival in non-small cell lung cancer (NSCLC). Lung cancer cells express opioid receptors. Opioids promote angiogenesis, tumour growth, and metastases, and shorten survival in animal models. METHODS: We examined retrospectively if long-term opioid requirement, independently of chronic pain, is associated with reduced survival in 209 patients with stage IIIB/IV NSCLC. Opioid doses were converted to average oral morphine equivalents (OME). Patients were stratified by proportion of time they reported severe pain, and required <5 or >/=5 mg day(-1) OME. Effects of pain, opioid requirement, and known prognostic variables on overall survival were analysed. RESULTS: Severe pain before chemotherapy initiation was associated with shorter survival (hazards ratio 1.39, 95% confidence interval, 1.02-1.87, P=0.035). The magnitude of pain and opioid requirement during first 90 days of chemotherapy were predictive of shorter survival: patients with no/mild pain and requiring <5 mg day(-1) OME had 12 months longer median survival compared with those requiring more opioids, experiencing more pain, or both (18 compared with 4.2-7.7 months, P

  • Link to Article
    publication date
  • 2014
  • published in
  • Drugs and Drug Therapy
  • Lung Cancer
  • Mortality
  • Pain
  • Retrospective Studies
  • Additional Document Info
  • 113
  • issue
  • Suppl 1